Despite few effective therapies, only a small percentage of patients diagnosed with myelodysplastic syndromes (MDS) in the United States are enrolled in prospective, interventional clinical trials. MDS-specific barriers to trial accrual include a high frequency of elderly patients with comorbid conditions, atypical disease features and uncertainty regarding the diagnosis (because other nonclonal processes also can cause dysplasia and cytopenias), a history of another nonmyeloid neoplasm resulting in therapy-related MDS, rapid disease recurrence after allogeneic stem cell transplantation, and an arbitrary division between MDS and acute myeloid leukemia. In addition, barriers to accrual that are common to other oncology populations, such as difficulty traveling to clinical trial enrollment sites and narrow trial eligibility criteria, also prevent patients with MDS from enrolling in studies. Collectively these barriers must be assessed systematically, and creative solutions are needed to improve outcomes for this needy patient population.
INTRODUCTION
In the United States, only a small percentage (approximately 3%) of adult patients with cancer enroll in interventional clinical trials. 1 As a result, approximately 20% of publicly funded prospective clinical trials fail due to a lack of accrual, and oncology has the lowest likelihood of drug approval from phase 1 among 14 major disease areas, despite public interest in access to novel agents as exemplified by "Right To Try" legislative proposals. [2] [3] [4] [5] Even at National Cancer Institutedesignated comprehensive cancer centers with large referral populations, approximately 20% to 40% of interventional trials accrue slowly (defined as the enrollment of fewer than 2 participants per year). 3, 6 Slow accrual may worsen as trials increasingly enroll small, molecularly defined patient subgroups. 3, 6 Barriers to clinical trial enrollment are a topic of active investigation because these obstacles are of concern to oncologists, policy makers, advocacy groups, trial sponsors, and professional societies, as well as to the general population, who call for more rapid progress in therapy for cancer. [7] [8] [9] [10] Specific subgroups of patients (older adults, racial and ethnic minority populations, and patients with chronic illnesses) are particularly underrepresented in clinical trials, thereby limiting the general applicability of results. [11] [12] [13] [14] As clinical investigators have focused on the myelodysplastic syndromes (MDS), we are deeply concerned by the small percentage of patients with MDS in the United States who enroll in prospective clinical trials. In the MDS setting, this low accrual is not due to a lack of motivation by clinicians to improve on current approaches. It is widely recognized that available therapies for MDS are inadequate, with no curative drugs and no new MDS-related drug indications approved by the US Food and Drug Administration (FDA) in more than a decade; therefore, new active drugs or drug combinations are needed.
Cancer December 15, 2018 per year expected to enroll if MDS studies were meeting the low 3% benchmark for adult oncology. Between 2005 and 2015, only 1052 patients with acute myeloid leukemia (AML) or MDS (the majority with post-MDS AML) were enrolled in trials submitted to the FDA. 18 The number of MDS slots on the 91 trials with "active" status registered with ClinicalTrials.gov on July 31, 2018 was 8862, or <5% of the estimated prevalence of MDS in the United States and Europe.
The dearth of new approaches and novel trial data in patients with MDS is so great that at the 2017 annual meeting of the American Society of Hematology, for what to our knowledge was the first time in many years, investigators did not submit enough high-quality abstracts for the society to create a free-standing "MDS novel therapy" oral session. At the American Society of Clinical Oncology's 2017 annual meeting, only 2 abstracts included MDS trial data; together, these studies enrolled 38 patients.
If there are so many patients with MDS in the United States, yet so few enroll on interventional trials, then, to echo the famous Fermi paradox: where are they? Herein, we have summarized barriers to clinical trial enrollment ( Fig. 1 The 3 medications currently approved by the FDA for MDS indications-azacitidine, decitabine, and lenalidomide-do help some patients, as do hematopoietic growth factors (MDS represents an off-label use for growth factors, but one that is supported by compendia listings and usually reimbursed by insurers). [20] [21] [22] Overall response rates for hypomethylating agents (HMAs) are within the range of 25% to 50%, whereas >65% of anemic patients with lowerrisk del(5q) MDS improve with the use of lenalidomide.
Rarely, exceptional responders to treatment with azacitidine or decitabine achieve normalization of blood counts and bone marrow blast percentages that last for years and are associated with a good performance status. 23 Less than 10% of patients with MDS who are treated with HMAs will be alive at 5 years, 24 but patients often embark on these therapies hoping they will be among the exceptional responders. Cancer December 15, 2018 Since azacitidine was approved by the FDA in 2004, lenalidomide in 2005, and decitabine in 2006, clinicians who routinely care for patients with MDS have developed a great deal of experience with these drugs. 26, 27 In contrast to AML, for which patients usually are referred early to a tertiary center, it is typical for patients to obtain MDS therapy primarily in community settings. Referrals to centers in which clinical trials are more commonly available may occur only among patients with more advanced stages of disease when available therapies have failed. Medications such erythropoiesis-stimulating agents (off-label use for MDS in the United States) and iron chelators are widely available and accrual to trials randomizing patients to receive these agents or not also can be difficult.
There are few nontrial options for the post-HMA MDS group other than supportive care. 28, 29 After HMAs fail, patients with higher risk disease have a median survival of <6 months, whereas those with lower risk disease have a median survival of only 15 months. [30] [31] [32] [33] In addition, such patients frequently are so diminished with regard to performance status, and have accumulated infections or other additional comorbid conditions, that they no longer are trial candidates.
There may be a bias against enrolling the MDS population into clinical trials due to concerns regarding the excessive toxicity of experimental drugs or drug combinations. One survey of patients with MDS and MDS health care practitioners found that providers were more likely to cite drug side effects as a reason for stopping treatment compared with patients. 34 The recently completed open-label North American Intergroup S1117 MDS study, in which patients with higher risk MDS were randomized to receive azacitidine monotherapy or azacitidine combined with either lenalidomide or vorinostat, reported that patients on the combination treatment arms were more likely to have undergone non-protocol-specified dose modifications or premature cessation due to toxicities, despite similar rates of higher grade adverse events reported on all arms. 35 
Patients With MDS Who Have Had Other Malignancies
Greater than 80% of disease-specific cancer clinical trials exclude patients who have been diagnosed with another form of cancer. 10, 36 Trial exclusion criteria related to other malignancies are a challenge for all trials but represent a major barrier for patients with MDS, because at least 10% to 20% of patients with MDS are diagnosed after a prior nonmyeloid neoplasm due to clonal hematopoietic selection by genotoxic chemotherapy or radiotherapy. 37, 38 Such patients are believed to have therapy-related MDS (t-MDS). t-MDS is a challenging MDS subtype due to a high prevalence of TP53 mutations and complex karyotypes, conferring chemoresistance and a grim prognosis. 39, 40 Therefore, clinical trials should be a high priority for this group.
However, many MDS trials exclude patients with t-MDS, often without a clear rationale. For example, patients with TP53-mutated MDS have a high response rate to HMAs, 41 but the median HMA response duration is brief, and therefore combinations of HMAs with novel agents are attractive. The Bcl-2 antagonist venetoclax is active in TP53-mutant and chromosome 17p-deleted lymphoid neoplasms, and preliminary results with combinations of HMA and venetoclax in patients with recurrent/refractory MDS and AML suggest efficacy. 42, 43 Therefore, combining an HMA with venetoclax is a strategy of interest in patients with t-MDS, given the role of TP53 mutations in this disease subset and the lack of efficacy of cytotoxic chemotherapy noted in this setting. Nevertheless, in the sole industry-sponsored trial of azacitidine plus venetoclax for treatment-naive patients with MDS (ClinicalTrials.gov identifier NCT02942290) excluded patients with t-MDS.
Sponsors often exclude patients who have been diagnosed with an invasive malignancy within 2, 3, or 5 years of trial enrollment (the high variability highlights the arbitrary nature of such criteria), reasoning that recurrence of the previous malignancy while the patient is enrolled on the MDS trial may make response assessment or adverse event adjudication more difficult. However, for phase 1 trials, the short dose-limiting toxicity assessment period (usually 28 days) that usually is the primary endpoint of such studies should not be influenced by a malignancy that occurred several years prior. In addition, even when an MDS diagnosis is made while a patient is actively being treated for another malignancy (eg, a patient who was undergoing treatment for a solid tumor was found to have more cytopenias than expected, and therefore a bone marrow biopsy was performed that demonstrated concomitant MDS), it still may be possible to assess response to an experimental MDS therapy if treatment for the solid tumor is no longer acutely required.
MDS Progression to AML or Disease Recurrence After Transplantation
Progression to AML represents a distinct challenge to MDS trial enrollment due to the often arbitrary Cancer December 15, 2018 distinction between AML and MDS trials. Patients with post-MDS AML may not have circulating blast cells. Such patients may be consented to an MDS trial, undergo a bone marrow aspirate and biopsy for screening, and then be found to have exceeded the World Health Organization (WHO) AML-defining myeloblast threshold of 20% in the bone marrow. They then may prove to be ineligible for the trial that they were being screened for if enrollment is restricted to patients with MDS. Often patients then are unwilling to undergo repeat bone marrow biopsy to screen for an AML trial.
Although some centers do screen patients with myeloid neoplasms for multiple trials at the same time, this can be logistically challenging, particularly if a trial requires sending a bone marrow sample to a central laboratory for biomarker analysis. Trials that allow patients with both MDS or AML to enroll are common, but only one arm of the trial may be open at a given time. Together, these developments too often result in a patient with AML with MDS features not qualifying for any clinical trials, and left with poor standard treatment options.
Similar challenges face patients with MDS who undergo allogeneic hematopoietic cell transplantation and subsequently develop disease recurrence. Unfortunately, this scenario is common because >40% of patients with MDS will develop disease recurrence within the first 2 years of allogeneic stem cell infusion. 44, 45 Some patients develop disease recurrence very early, before graft-versus-host disease (GVHD) prophylaxis has been tapered; others with recurrent disease may continue to require immunosuppression for chronic GVHD. These patients often are excluded from clinical trials because of the unknown effect of GVHD or immunosuppression on the behavior of the MDS or the study drug, and also because of an increased risk of infection.
Distance or Commuting Time to the Trial Center
Commuting times are growing longer and traffic is increasing in nearly all of the major cities in the United States. Between 2013 and 2014 (the most recent year for which comprehensive data are available), commuting times increased in 95 of the largest 100 urban metropolitan areas. 46 Given current low funding levels for public transportation in the United States, it may continue to become more difficult for individuals to travel from suburban or rural locations to dense city centers where many academic medical centers that offer trials are located. For example, in the Boston metropolitan area, a 10-mile automobile commute into the city center at a peak time can require >1 hour in each direction, and bus ride times have increased by a median of 39% within the last 8 years. 47 The New York City subway system now has the worst ontime performance of any major system in the world, 48 resulting in frequently delayed or missed appointments for patients. In less densely populated communities, patients may have to travel for hours, and find local lodging, to receive specialized care for MDS, including trial access.
Difficulty and expense of commuting to a study site is an established, important barrier to trial enrollment. 49 Some MDS trials require patients to come to the research center for 7 consecutive days (the standard azacitidine schedule), which can be a burden. One ongoing trial of an HMA combination therapy (ClinicalTrials.gov identifier NCT03072043) requires patients to attend the outpatient clinic for treatment or evaluation for at least 14 of the first 28 days. The travel burden is especially heavy for the elderly MDS population (the median age at the time of diagnosis of MDS is >70 years 50, 51 ), who often cannot drive themselves due to visual or physical limitations and whose social support structure may be fragile. Reimbursement from sponsors for travel expenses may be welcomed by participants, and the majority of ethicists do not consider small payments to defray clinical trialrelated expenses to be coercive, but relief of financial burden does not overcome logistical challenges.
Patients With Atypical Features, an Unclear Diagnosis, or Those in Whom It Is Too Early to Consider Therapy
MDS can be a difficult diagnosis to make, 52, 53 and patients with cytopenias often are referred to specialty centers if there is diagnostic uncertainty, such as patients with mild bone marrow dysplasia that is not extensive enough to meet WHO minimal diagnostic criteria for MDS. 54, 55 Patients in whom a diagnosis cannot be made confidently are unable to enroll in interventional trials. In addition, if there is a perception that a patient was referred to the tertiary center primarily for diagnostic clarification, the patient may not be referred back when their disease worsens.
Some patients clearly have a myeloid neoplasm, but it is at an early stage when therapy is not indicated. This subgroup includes patients with chronic myelomonocytic leukemia without cytopenias; patients with mean cell volume elevation without anemia; or those with mild, asymptomatic cytopenias. Increasingly, with the expanded clinical use of next-generation sequencing panels targeting panels of myeloid-associated mutations, this subgroup also includes patients with the MDS precursor Cancer December 15, 2018 states clonal hematopoiesis of indeterminate potential (CHIP) or clonal cytopenias of undetermined significance (CCUS). [56] [57] [58] Trials concerned with preventing disease progression are of interest in patients with early disease states, and currently are being conducted in several hematologic malignancy precursor disease settings (eg, monoclonal gammopathy of undetermined significance/smoldering multiple myeloma, early-stage chronic lymphoid leukemia (CLL)/monoclonal B-cell lymphocytosis). 59, 60 However, to the best of our knowledge, there are few interventional trials to date for CHIP or CCUS. In addition, MDS trials often exclude patients with myeloproliferative features, bone marrow fibrosis, or germline syndromes that predispose to MDS.
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Lack of Trial Slots at Times When Patients Are Available, and Lack of Suitable Patients at Times When Trial Slots Are Available
For the most promising clinical trials, many investigators and centers often express interest in participation. Because industry sponsors hope to maintain a good relationship with major treating centers and so-called "key opinion leaders," 63 they may open trials at too many centers to be practical.
Although this barrier is not specific to patients with MDS, several recent MDS phase 1 trials have opened at more than a dozen large centers, which is impractical for an early-phase study. 64 Enrollment slots in phase 1 trials are limited by typical 3+3 dose escalation designs, and therefore there are limited opportunities for investigators to enroll patients. Often, "first-come-first-serve" processes create intense competition for slots. In one ongoing MDS phase 1 trial that is investigating a targeted drug for a common recurrent mutation class, each time an e-mail goes out from the Contract Research Organization stating that a new cohort has opened, all enrollment slots are reserved within minutes.
The lack of a slot on a study at a time when a center has an eligible patient who is motivated to enroll on a clinical trial is frustrating for all concerned. In contrast, some centers complain that whenever a study slot opens, it is taken by another center before they can identify a suitable patient. There is not an established, "fair" way to handle this situation, due to many competing priorities. This may result in slow accrual that has local administrative consequences for investigators, and impacts enthusiasm for study personnel to consider a given clinical trial for patients because available slots are assumed to be unavailable.
Trials That Are Not Interesting Enough, Populations That Do Not Exist, and Placebo Controls
Not all clinical trials are created equal. Trials investigating targeted agents for common recurrent mutations, or trials studying agents with a proven track record in other diseases, tend to generate excitement. In contrast, studies of "me-too" agents or molecules with a speculative mechanism are less motivating for investigators. For example, pharmaceutical companies continue to develop new nucleoside analogues for the treatment of MDS and AML, which may offer a degree of benefit over existing agents but are unlikely to be transformative given the numerous nucleoside analogues explored since the 1940s.
Investigators may become skeptical of new agents if the first few patients they enroll on a clinical trial do not respond or experience serious adverse events, an effect compounded when a site may receive slots only intermittently and not gain experience in using a new regimen. Investigators also may have agreed to participate in a clinical trial believing that they will have a larger population of patients than they actually do. "Lasagna's Law," which first was proposed in the 1970s, states that investigators systematically overestimate the pool of available patients who will meet inclusion criteria for a proposed study, and enthusiasm for a trial dissipates with the realization that original estimates were misguided. 65, 66 For example, accrual to prospective controlled iron chelation trials in red cell transfusion-dependent patients with MDS has proven challenging, in part because many clinicians lack equipoise regarding the benefit and risk of iron chelation in this population 67 and also because patients must have severe enough bone marrow failure to require regular transfusions yet still have lower risk disease so they might live long enough for chelation to demonstrate benefit. The landmark placebo-controlled trial of the chelator deferasirox (ClinicalTrials.gov identifier NCT00940602) began in 2009 and has not yet reported results; it took many more years to accrue to this study than originally planned, and the sample size had to be reduced several times from the original goal. In part this was because the FDA approved the drug in 2005 and thus it was widely available to clinicians who felt strongly about the importance of iron chelation in patients with MDS.
Although offering scientific rigor, placebo controls may be unappealing to many investigators and patients given the current dismal treatment landscape for individuals with recurrent/refractory MDS, particularly in the United States and especially if there is no opportunity for cross-over to active therapy. For example, for the phase Cancer December 15, 2018 3 placebo-controlled MEDALIST study of luspatercept (ClinicalTrials.gov identifier NCT02631070), only 13 of the 74 study sites were located within the United States and the majority of patients were accrued in Europe, in part because the trial required nearly 1 year of blinded therapy without a cross-over design. Patients from some minority groups or other vulnerable populations who have historically been exploited by unethical investigations may have a fear of "being a guinea pig" if a trial includes a placebo. 68 The possibility of randomization to "standard of care" in MDS settings for which there are limited treatment options beyond transfusion support also can be a barrier.
Although trials enrolling patients with MDS and exploring >100 different drugs are listed on the ClinicalTrials.gov Web site as "open" and "accruing," that number may be misleading; many trials included in a similar summary compiled in 2013 closed and were never reported. 69, 70 In addition to a lack of efficacy or slow trial accrual, reasons for closure have included challenging regulatory approval guidelines and sponsors with unstable financial backing.
Narrow Enrollment Criteria and Sponsors With Limited Experience in MDS
It is widely recognized that eligibility criteria for many clinical trials are excessively narrow. 10 Exclusion criteria that focus on minor laboratory abnormalities, human immunodeficiency virus infection, Zubrod performance status other than 0 or 1, or any history of another tumor needlessly exclude patients who otherwise might be good trial candidates. One analysis of 98 randomized studies conducted in patients with hematologic malignancies, including MDS, found that eligibility criteria had little to do with what was known about the investigational drug's toxicities or with adverse events actually realized in the trials. 71 Inclusion and exclusion criteria may be "cut and paste" from one trial to another, without consideration of the specific circumstances of each trial.
SWOG recently assessed 2361 patients who were enrolled on 13 interventional MDS or leukemia studies. Approximately 10% of enrolled patients later were found to have been ineligible due to minor laboratory abnormalities or assessments out of the treatment window, but only after they had been treated similarly to eligible patients. The ineligible patients had rates of grade 3 to 5 adverse events, response rates, and overall survival similar to those of eligible patients. 72 One ongoing multinational trial of an HMA combination for patients who previously had failed treatment with an HMA requires patients to have been administered the HMA for higher risk disease and excludes patients who initially were treated with an HMA at a time when they had lower risk disease, even if they have higher risk features at the time of proposed clinical trial enrollment. Although this exclusion reflects the HMA label in some countries, which is restricted to higher risk disease, the eligibility criteria apply to all centers, even in locations in which HMAs commonly are used for patients with lower risk disease. Other trials of MDS populations with "HMA failure" use eligibility criteria that require patients to have higher risk disease at the time of study entry, defined as higher risk categories of the original or revised International Prognostic Scoring System, despite the inaccuracy of these systems in previously treated patients. 31 These types of exclusion are not based in biology, and we believe they make little sense.
Trial sponsors with solid tumor experience may propose trials with exclusion criteria that are appropriate for the solid tumor setting but not appropriate for patients with MDS. For example, between 2015 and the present, we have noted multiple trial synopses for immune checkpoint inhibitors that excluded patients with cytopenias, which is not an appropriate exclusion criterion for patients with MDS, in whom the disease is defined by cytopenias.
Potential Solutions
Solutions to overcome these barriers to MDS trial accrual are not straightforward and require deliberate cooperative efforts among sponsors, investigators, regulators, and patient groups. To begin with, broader entry criteria that more closely reflect real-world populations of patients with MDS are greatly needed. 10 For example, MDS trials should not exclude patients who recently had another malignancy if the MDS response to the study drug is likely to still be assessable during the time horizon of the study, nor should a specific degree of cytopenias or posttreatment International Prognostic Scoring System risk group dictate eligibility if the degree of cytopenia or risk group is unlikely to influence efficacy or safety.
One particularly interesting trial that accrued patients with MDS to a combination of an HMA and vorinostat was designed with a disruptive approach to eligibility criteria: it required enrolling patients who were ineligible for other trials due to poor performance status, organ dysfunction, or another neoplasm. 73 Response rates, adverse events, and survival for these patients were found to be similar to comparable trials of combination therapies with more restrictive eligibility criteria. Having such safety-valve trials, or requiring clinical trials to have Cancer December 15, 2018 "real-world" arms with more permissive eligibility requirements, can augment accrual and avoid the criticism that study participants are "cherry picked." To do this would require agreement from regulators that such designs would complement submissions for approval and not be used punitively; buy-in from sponsors to support additional studies or study arms; and increased attention from site study staff in accurately attributing adverse events within the setting of comorbid conditions. FDA regulators have shown openness to trials with much broader eligibility criteria. 74 Trials for special disease subsets commonly excluded from clinical trials also are welcome, including MDS/ myeloproliferative neoplasm (MPN) overlap syndromes. As part of efforts to increase the number of MDS/MPNspecific clinical trials or MDS/MPN cohorts in MDS or MPN trials, the MDS/MPN International Working Group published consensus response criteria for MDS/ MPN. 75 This led to the development of several new trials dedicated to MDS/MPN 76, 77 and to the first international basket trial for MDS/MPN will open in 2019. Other important subsets of underserved patients include CHIP/CCUS, MDS arising in patients with congenital bone marrow failure conditions, or MDS in patients with germline predispositions to myeloid neoplasia. The latter 2 groups are recognized in the 2016 revision to WHO criteria, which may augment their identification. 55 Ensuring that interventional trials are available nearer to patients' homes also can reduce the burden of participating in a trial. There have been important efforts toward expanding trials to community-based practices, such as the large trial portfolios of the US Oncology and the Sarah Cannon Research Institute clinical trials networks, and the 2015 transformation of the National Cancer Institute Cooperative Group program into the National Clinical Trials Network. Expansion specific to hematological malignancies has been performed on a limited basis in several pilot projects, such as the Leukemia and Lymphoma Society's Blood Cancer Research Partnership (https://www.lls.org/research/clinical-trials-division). Nonetheless, with reduced federal funding of the National Clinical Trials Network and low patient reimbursement rates for trial sites, the number of centers participating in these trials may diminish with time.
Even if a study is not formally conducted at a local center, some assessments can be performed in local practices to diminish the travel burden for participants. For example, weekly blood counts and transfusions can be performed in a local laboratory or clinic and do not necessarily require a trip to the study center. Expanding "telehealth" also might help decrease study visits.
Unfortunately, despite careful federal regulatory oversight of all laboratories and clinical sites, involving local providers who operate outside of the purview of a specific site's Office for Human Research Protections agreement or who are directly monitored by the study center often causes discomfort for institutional review boards and sponsors. This cooperation in care is essential given the current treatment landscape. The involvement of patients and advocacy groups in trial design also is important. Finally, we can learn from disease-specific registries, which complement interventional trials.
Conclusions
MDS clinical trial accrual is suboptimal, especially in the United States, and obstacles to enrollment are representative of challenges to trial accrual across the field of hematology-oncology. There are numerous barriers to trial accrual and development that need to be systematically assessed, and creative solutions are needed to improve outcomes for this needy patient population.
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